Relaxin Therapy for Atrial Fibrillation

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 208 participants.

Also called NCT07359872

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 208 participants (planned count) (from the registry)
Sponsor
Deeptankar DeMazumder (from the registry)
Registry
  • NCT NCT07359872
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07359872. Randomized; quadruple masking; primary purpose treatment. Start 2027-01-01 (anticipated); primary completion 2030-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Relaxin Therapy for Atrial Fibrillation
Acronym
Relax-in-AF
Condition
Atrial Fibrillation (AF)
Condition
Arrhythmia
Condition
Oxidative Stress
Condition
Stroke
Condition
Major Cardiovascular Event
Condition
Heart Failure
Condition
Ablation of Atrial Fibrillation
Intervention (Drug)
Relaxin
Intervention (Drug)
Placebo
Lead sponsor
Deeptankar DeMazumder (class: US federal agency)
Collaborator
Relaxera Pharmaceuticals (class: not stated)
Collaborator
McGowan Institute for Regenerative Medicine, University of Pittsburgh (class: not stated)
Collaborator
Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (class: not stated)

Record details

Record id
cardio:ct-nct07359872
Content hash
df61e07c4c6448f75b6dbf0532db81f23a617984668bf267274b4d28fbce99da